Picton Mahoney Asset Management increased its stake in shares of Insmed Incorporated (NASDAQ:INSM – Free Report) by 7.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 48,897 shares of the biopharmaceutical company’s stock after purchasing an additional 3,354 shares during the period. Picton Mahoney Asset Management’s holdings in Insmed were worth $3,374,000 as of its most recent SEC filing.
A number of other institutional investors have also made changes to their positions in the stock. CIBC Asset Management Inc grew its stake in shares of Insmed by 3.5% during the third quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 149 shares during the period. Abel Hall LLC grew its stake in shares of Insmed by 4.7% during the fourth quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company’s stock worth $230,000 after purchasing an additional 151 shares during the period. Commerce Bank grew its stake in shares of Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after purchasing an additional 163 shares during the period. Steward Partners Investment Advisory LLC grew its stake in shares of Insmed by 65.2% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 163 shares during the period. Finally, M&T Bank Corp grew its stake in Insmed by 5.6% in the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company’s stock valued at $217,000 after acquiring an additional 166 shares during the period.
Wall Street Analyst Weigh In
A number of research analysts have issued reports on the company. Truist Financial boosted their target price on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company boosted their price target on Insmed from $85.00 to $107.00 and gave the company an “overweight” rating in a report on Wednesday, February 19th. HC Wainwright restated a “buy” rating and issued a $90.00 price target on shares of Insmed in a report on Friday, February 21st. JPMorgan Chase & Co. boosted their price target on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Finally, Morgan Stanley boosted their price target on Insmed from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Thursday, February 6th. One research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, Insmed presently has an average rating of “Moderate Buy” and a consensus target price of $93.33.
Insider Activity
In related news, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $65.91, for a total transaction of $220,403.04. Following the sale, the insider now owns 102,766 shares of the company’s stock, valued at $6,773,307.06. This represents a 3.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO William Lewis sold 18,750 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $81.03, for a total value of $1,519,312.50. Following the sale, the chief executive officer now directly owns 334,186 shares in the company, valued at $27,079,091.58. This represents a 5.31 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 550,957 shares of company stock valued at $42,859,028. 4.60% of the stock is owned by insiders.
Insmed Price Performance
Insmed stock opened at $76.55 on Friday. Insmed Incorporated has a 12 month low of $21.92 and a 12 month high of $84.91. The stock’s 50 day moving average is $76.17 and its 200-day moving average is $73.71. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. The company has a market capitalization of $13.86 billion, a price-to-earnings ratio of -13.69 and a beta of 1.28.
Insmed (NASDAQ:INSM – Get Free Report) last posted its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Equities research analysts expect that Insmed Incorporated will post -4.56 EPS for the current year.
Insmed Profile
Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.
Recommended Stories
- Five stocks we like better than Insmed
- What does consumer price index measure?
- Ignore Reports, Apple Won’t Install Starlink with iOS 18.3
- What Are Dividend Challengers?
- Casey’s Uptrend Remains Strong—New Highs on the Horizon
- How to Most Effectively Use the MarketBeat Earnings Screener
- Taiwan Semiconductor’s Huge U.S. Move—Stock Impact Ahead
Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed Incorporated (NASDAQ:INSM – Free Report).
Receive News & Ratings for Insmed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insmed and related companies with MarketBeat.com's FREE daily email newsletter.